Access · International

Personal import allowances, compared — a second dataset

Access › International personal import telehealth MHRA EMA NHS

Wiki

crossref_checkTL3Wiki editor14 Sep 2025#1

Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by impurity_table on 29 Oct 2025.

7 Nov 2025 — Birkeland: Plain-language pass on the opening paragraph.
23 Nov 2025 — aliquot_line: Corrected an arithmetic slip in the second example.
29 Oct 2025 — impurity_table: Added the limitations paragraph that review asked for.

Editors: Birkeland, aliquot_line, impurity_table, crossref_check

Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable.

A coverage question with the paperwork detail included, since that is what determines the answer.

Denial received, with a stated reason. My reading of the reason is that it tells me exactly what to submit next, which is the useful thing about a well-written denial.

Before I spend a week on it: is my reading of the stated criterion correct, and is there a documented precedent for this specific ground?

2 likes 10mo

j.hartmannTL2 Moderator20 Sep 2025 · edited#2

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

0 likes 10mo

KnowltonTL3Regular24 Sep 2025#3

j.hartmann, post #2: Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago. Go to post

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

21 likes in reply to #2 10mo

s.achebeTL2 Moderator27 Sep 2025#4

Knowlton, post #3: Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had been repeating something I had not checked carefully enough. Go to post

the opening post answers the question as asked. The question underneath it is different.

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

9 likes in reply to #3 10mo

v.nascimentoTL2 Moderator1 Oct 2025#5

I read post #3 twice before replying, because I had assumed the opposite.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

0 likes 10mo

n.rahimiTL2 Moderator4 Oct 2025 · edited#6

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

30 likes 10mo

p.amankwahTL2 Moderator7 Oct 2025#7

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

15 likes 10mo

i.coelhoTL2 Moderator10 Oct 2025#8

n.rahimi, post #6: Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up. Go to post

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

5 likes in reply to #6 10mo

c.tullochTL2 Moderator13 Oct 2025#9

Coming back to post #7, because the follow-up matters more than the original answer.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

0 likes 9mo

KLindqvistTL4 Moderator16 Oct 2025#10

Picking up post #7: that is the part I would want checked first.

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

22 likes 9mo

d.achebeTL2 Moderator18 Oct 2025#11

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

16 likes 9mo

DKwiatkowskiTL321 Oct 2025#12

Collapsed as off-topic by two members at trust level 3 or above

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

f.piresTL2 Moderator24 Oct 2025#13

KLindqvist, post #10: Picking up post #7: that is the part I would want checked first. Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent. Go to post

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

0 likes in reply to #10 9mo

NorringtonTL3Regular26 Oct 2025#14

f.pires, post #13: Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear. Go to post

On post #10 — agreed on the reasoning, with one qualification.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

3 likes in reply to #13 9mo

w.verhoevenTL2 Moderator29 Oct 2025#15

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

11 likes 9mo

NicolaidesTL3Regular31 Oct 2025#16

Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).

23 likes 9mo

r.weissTL2 Moderator3 Nov 2025 · edited#17

post #16 is right about the mechanism and I think understates the practical bit.

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

0 likes 9mo

aliquot_lineTL3Regular5 Nov 2025#18

j.hartmann, post #2: Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago. Go to post

Worth separating two things that post #14 runs together.

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

1 like in reply to #2 9mo

am.wikstromTL2 Moderator8 Nov 2025#19

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

30 likes 9mo

d.magalhesTL2Member10 Nov 2025#20

Coming back to post #18, because the follow-up matters more than the original answer.

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

0 likes 9mo

ro.friskTL2 Moderator12 Nov 2025#21

Coming back to post #19, because the follow-up matters more than the original answer.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

0 likes 8mo

dr_seongTL3Physician14 Nov 2025#22

Picking up post #19: that is the part I would want checked first.

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

0 likes 8mo

i.almeidaTL2 Moderator17 Nov 2025#23

Nicolaides, post #16: Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials). Go to post

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

12 likes in reply to #16 8mo

orbitrap_olaTL3Mass spectrometrist19 Nov 2025#24

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

4 likes 8mo

n.kravchenkoTL2 Moderator21 Nov 2025#25

I read post #23 twice before replying, because I had assumed the opposite.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

1 like 8mo

w.novakTL3Regular23 Nov 2025#26

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

0 likes 8mo

f.weissTL2 Moderator26 Nov 2025 · edited#27

ro.frisk, post #21: Coming back to post #19, because the follow-up matters more than the original answer. Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound. Go to post

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

18 likes in reply to #21 8mo

customs_ledgerTL3Regular28 Nov 2025#28

post #27 is right about the mechanism and I think understates the practical bit.

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

7 likes in reply to #16 8mo

j.falkTL2 Moderator30 Nov 2025#29

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

0 likes 8mo

y.mensahTL3Wiki editor2 Dec 2025#30

s.achebe, post #4: the opening post answers the question as asked. The question underneath it is different. Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt. Go to post

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

19 likes in reply to #4 8mo

Sponsored Sigma-Aldrich — certified reference materialsReference standards, analytical reagents and certified materials for method calibration. If you are validating a method, this is where the standard comes from.Reference standards →